IGC Pharma, Inc.
IGC· NYSE
IGCIGC Pharma, Inc.
Filed Nov 8, 2013 · 10-Q · 39 days after period end · 0001185185-13-002348
| Metric | Q2 2014 | Q2 2010 |
|---|---|---|
| Revenue | $1.13M | $1.68M |
| Net Income | -$615.19K | -$856.26K |
| EPS Diluted | -$0.09 | -$0.06 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IGC Pharma, Inc. · CIK 1326205 · Engraved from SEC EDGAR
ended Sep 30, 2013 · filed Nov 8, 2013 · 39 d after period end
